Oncosense is a life sciences business that identifies, acquires and develops world-class compounds and technologies for the treatment of cancer. We then manage the preclinical and early clinical development of drug candidates whilst pursuing collaborative opportunities with pharmaceutical partners.
- 15 Jun 2009
- 05 Jun 2009
- 04 Jun 2009
| Latest share price | 3.50 GBp
20 min delayed |
Our vaccines business has an exclusive worldwide licence to technology that enhances the performance of therapeutic DNA vaccines for cancer.
We have an exclusive worldwide licence to the medical use of a series of cytotoxic (cell killing) agents based upon organometallic complexes formed by the precious metal ruthenium.
Our ribozyme technology has been shown to suppress expression of CCR5 and CXCR4, two cellular receptors for HIV. The Company is currently seeking to divest or out-licence this technology.